The Combination of Alisporivir plus an NS5A Inhibitor Provides Additive to Synergistic Anti-Hepatitis C Virus Activity without Detectable Cross-Resistance

Udayan Chatterji(Scripps Research Institute), Philippe Gallay(Scripps Research Institute), Clifford A. Brass(Novartis (Switzerland)), Nikolai V. Naoumov(Novartis (Switzerland)), Katarzyna Gawlik, Kelly A. Wong(Novartis (United States)), Jose A. Garcia-Rivera(Naval Medical Research Command), Weidong Zhong(Novartis (United States)), James Baugh(Scripps Research Institute)
Antimicrobial Agents and Chemotherapy
April 1, 2014
Cited by 37


Related Papers